Minerva Neurosciences, Inc. (NERV) is a Biotechnology company in the Healthcare sector, currently trading at $6.18. It has a SharesGrow Score of 46/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
Analyst consensus target is NERV = $5 (-19.1% upside).
Valuation: NERV trades at a trailing Price-to-Earnings (P/E) of -0.2 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.01.
Net income is $293M (loss), growing at -6793.1%/yr. Net profit margin is 0% (thin). Gross margin is 0% (+0 pp trend).
Balance sheet: total debt is $65M with negative equity of -$141M — this means total liabilities exceed total assets. This is a warning sign that may indicate accumulated losses, aggressive share buybacks, heavy debt financing, or aggressive dividend payouts. Companies like McDonald's and Starbucks also carry negative equity due to buybacks and dividends, but investors should assess whether the business generates sufficient cash flow to service its debt and sustain payouts. Current ratio is 36.29 (strong liquidity). Debt-to-assets is 66.3%. Total assets: $98M.
Analyst outlook: 5 / 7 analysts rate NERV as buy (71%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 67/100 (Pass), Growth 15/100 (Fail), Past 25/100 (Fail), Health 100/100 (Pass), Moat 28/100 (Fail), Future 49/100 (Partial), Income ?/100 (Fail).
